146 related articles for article (PubMed ID: 12401901)
1. U.S. Food and Drug Administration drug approval summaries: imatinib mesylate, mesna tablets, and zoledronic acid.
Cohen MH; Dagher R; Griebel DJ; Ibrahim A; Martin A; Scher NS; Sokol GH; Williams GA; Pazdur R
Oncologist; 2002; 7(5):393-400. PubMed ID: 12401901
[TBL] [Abstract][Full Text] [Related]
2. Oral administration of mesna with ifosfamide.
Goren MP
Semin Oncol; 1996 Jun; 23(3 Suppl 6):91-6. PubMed ID: 8677457
[TBL] [Abstract][Full Text] [Related]
3. Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases.
Ibrahim A; Scher N; Williams G; Sridhara R; Li N; Chen G; Leighton J; Booth B; Gobburu JV; Rahman A; Hsieh Y; Wood R; Vause D; Pazdur R
Clin Cancer Res; 2003 Jul; 9(7):2394-9. PubMed ID: 12855610
[TBL] [Abstract][Full Text] [Related]
4. Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors.
Dagher R; Cohen M; Williams G; Rothmann M; Gobburu J; Robbie G; Rahman A; Chen G; Staten A; Griebel D; Pazdur R
Clin Cancer Res; 2002 Oct; 8(10):3034-8. PubMed ID: 12374669
[TBL] [Abstract][Full Text] [Related]
5. Continuous subcutaneous administration of mesna to prevent ifosfamide-induced hemorrhagic cystitis.
Markman M; Kennedy A; Webster K; Kulp B; Peterson G; Belinson J
Semin Oncol; 1996 Jun; 23(3 Suppl 6):97-8. PubMed ID: 8677458
[TBL] [Abstract][Full Text] [Related]
6. Gleevec for the treatment of chronic myelogenous leukemia: US. Food and Drug Administration regulatory mechanisms, accelerated approval, and orphan drug status.
Cohen MH; Moses ML; Pazdur R
Oncologist; 2002; 7(5):390-2. PubMed ID: 12401900
[TBL] [Abstract][Full Text] [Related]
7. Imatinib mesylate and zoledronic acid in androgen-independent prostate cancer.
Tiffany NM; Wersinger EM; Garzotto M; Beer TM
Urology; 2004 May; 63(5):934-9. PubMed ID: 15134984
[TBL] [Abstract][Full Text] [Related]
8. Review of Advances in Uroprotective Agents for Cyclophosphamide- and Ifosfamide-induced Hemorrhagic Cystitis.
Matz EL; Hsieh MH
Urology; 2017 Feb; 100():16-19. PubMed ID: 27566144
[TBL] [Abstract][Full Text] [Related]
9. U.S. Food and Drug Administration Drug Approval Summary: conversion of imatinib mesylate (STI571; Gleevec) tablets from accelerated approval to full approval.
Cohen MH; Johnson JR; Pazdur R
Clin Cancer Res; 2005 Jan; 11(1):12-9. PubMed ID: 15671523
[TBL] [Abstract][Full Text] [Related]
10. Prevention of further cyclophosphamide induced hemorrhagic cystitis by hyperbaric oxygen and mesna in guinea pigs.
Korkmaz A; Oter S; Deveci S; Goksoy C; Bilgic H
J Urol; 2001 Sep; 166(3):1119-23. PubMed ID: 11490309
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological and histopathological study of cyclophosphamide-induced hemorrhagic cystitis - comparison of the effects of dexamethasone and Mesna.
Morais MM; Belarmino-Filho JN; Brito GA; Ribeiro RA
Braz J Med Biol Res; 1999 Oct; 32(10):1211-5. PubMed ID: 10510257
[TBL] [Abstract][Full Text] [Related]
12. Neutrophils contribute to the pathogenesis of hemorrhagic cystitis induced by ifosfamide.
Dornelas-Filho AF; Pereira VBM; Wong DVT; Nobre LMS; Melo AT; Silva CMS; Wanderley CWS; Nour ML; Araújo LCNC; Silva RO; Pinto FMM; Bingana RD; Souza MHLP; Alencar NMN; Silva PGB; Alves APNN; Almeida PRC; Cunha FQ; Lima-Júnior RCP
Int Immunopharmacol; 2018 Sep; 62():96-108. PubMed ID: 29990699
[TBL] [Abstract][Full Text] [Related]
13. [Ifosfamide-induced hemorrhagic cystitis and its prevention by mesna].
Matsumoto S; Kawaguchi N; Manabe J; Kuroda H; Shimoji T
Gan To Kagaku Ryoho; 1995 Jun; 22(7):965-8. PubMed ID: 7794006
[No Abstract] [Full Text] [Related]
14. The efficacy of mesna (2-mercaptoethane sodium sulfonate) as a uroprotectant in patients with hemorrhagic cystitis receiving further oxazaphosphorine chemotherapy.
Andriole GL; Sandlund JT; Miser JS; Arasi V; Linehan M; Magrath IT
J Clin Oncol; 1987 May; 5(5):799-803. PubMed ID: 3106585
[TBL] [Abstract][Full Text] [Related]
15. Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma.
Goodman VL; Rock EP; Dagher R; Ramchandani RP; Abraham S; Gobburu JV; Booth BP; Verbois SL; Morse DE; Liang CY; Chidambaram N; Jiang JX; Tang S; Mahjoob K; Justice R; Pazdur R
Clin Cancer Res; 2007 Mar; 13(5):1367-73. PubMed ID: 17332278
[TBL] [Abstract][Full Text] [Related]
16. Incidence of hemorrhagic cystitis after cyclophosphamide therapy with or without mesna: A cohort study and comprehensive literature review.
Almalag HM; Alasmari SS; Alrayes MH; Binhameed MA; Alsudairi RA; Alosaimi MM; Alnasser GA; Abuzaid RA; Khalil N; Abouzaid HH; Alarfaj AS
J Oncol Pharm Pract; 2021 Mar; 27(2):340-349. PubMed ID: 32356687
[TBL] [Abstract][Full Text] [Related]
17. The protective effect of 2-mercapto-ethane sulfonate (MESNA) on hemorrhagic cystitis induced by high-dose ifosfamide treatment tested by a randomized crossover trial.
Sakurai M; Saijo N; Shinkai T; Eguchi K; Sasaki Y; Tamura T; Sano T; Suemasu K; Jett JR
Jpn J Clin Oncol; 1986 Jun; 16(2):153-6. PubMed ID: 3090314
[TBL] [Abstract][Full Text] [Related]
18. Imatinib mesylate: in the treatment of gastrointestinal stromal tumours.
Croom KF; Perry CM
Drugs; 2003; 63(5):513-22; discussion 523-4. PubMed ID: 12600228
[TBL] [Abstract][Full Text] [Related]
19. Combined intravenous and oral mesna in outpatients treated with ifosfamide.
Goren MP; McKenna LM; Goodman TL
Cancer Chemother Pharmacol; 1997; 40(5):371-5. PubMed ID: 9272112
[TBL] [Abstract][Full Text] [Related]
20. Comparision of uroprotective activity of reduced glutathione with mesna in ifosfamide induced hemorrhagic cystitis in rats.
Ali SA; Danda SK; Basha SA; Rasheed A; Ahmed O; Ahmed MM
Indian J Pharmacol; 2014; 46(1):105-8. PubMed ID: 24550594
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
